NCT Number: NCT02674308
Entyvio (Vedolizumab) Long Term Safety Study
The purpose of this study is to assess the long-term safety of vedolizumab versus other biologic agents in participants with Ulcerative Colitis (UC) or Crohn's Disease (CD).
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Krankenhaus Der Elisabethinen Linz Gmbh, Oberosterreich, Austria
About this study
The drug being tested in this prospective, observational study is called vedolizumab. Vedolizumab is being used to treat people who have UC or CD. This study will look at the long-term safety of vedolizumab versus other biologic agents in participants with UC or CD. The study will enroll approximately 5000 participants. All participants enrolled in this will belong to one of the two treatment group:
- Vedolizumab
- Other Biologic Agents -adalimumab, certolizumab pegol.
Golimumab and infliximab. Study drugs will be prescribed by the physician according to local prescribing information in the participating countries. This multi-centre trial will be conducted worldwide. The overall time to participate in this study is 7 years. Participants will make visits at every 6 months to their treating physician.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Signed informed consent, by the participant or a legally acceptable representative.
- Aged at least 18 years.
- Initiating vedolizumab or another biologic agent for UC or CD.
- Signed release form, by the participant or a legally acceptable representative, permitting abstraction of the participant's medical records at Baseline and during participation in the study.
Exclusion criteria
- The participant is enrolled in a clinical trial in which treatment for CD or UC is managed through a protocol.
- Prior treatment with vedolizumab.
- Any other reason that, in the Investigator's opinion, makes the participant unsuitable to participate in this study.
Treatment and study plan
Other Biologic Agents
OtherOther biologic agents include: Adalimumab, Certolizumab pegol, Golimumab, and Infliximab
Primary outcomes
-
Percentage of Participants with Adverse Events of Special Interest
Time frame: 7 years
Adverse events of special interest in this study includes serious and opportunistic infections, gastrointestinal infections, respiratory infections, other clinically significant infections: malignancies; infusion-related reactions and hypersensitivity, hepatic injury; psoriasis and other skin events, other SAEs and adverse reactions.
Secondary outcomes
-
Disease Severity in Ulcerative Colitis (UC) Participants
Time frame: Baseline and at every 6 months (up to 7 years)
Disease severity will be measured using the Mayo score for ulcerative colitis and is ranged from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores: stool frequency, rectal bleeding and physician rating of disease activity, each ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe).
-
Disease Severity in Crohn's Disease (CD) Participants
Time frame: Baseline and at every 6 months (up to 7 years)
Disease severity will be measured using the Harvey-Bradshaw Index (HBI) for crohn's disease. HBI is used in the assessment and quantification of symptoms and the present level of disease activity of participants with Crohn's disease. It is a validated clinical index for Crohn's disease,HBI score consists of clinical parameters of general well-being (0= very well 1=slightly below average, 2=poor, 3=very poor, 4=terrible); abdominal pain (0=none, 1=mild, 2=moderate, 3=severe); number of liquid stools per day; abdominal mass (0=none, 1=dubious, 2=definite, 3=tender); and complications (8 items: arthralgia, uveitis, erythema nodosum, aphthous ulcers, pyoderma gangrenosum, anal fissures, new fistula, abscess [score 1 per item]).Lower scores indicate better well-being. The scores are classified as: <5=remission, 5-7=mild disease, 8-16=moderate disease and >16=severe disease. Minimum score is 0 and no pre-specified maximum score as it depends on the number of liquid stools.
-
Participant Reported Quality of Life Assessment Using Short Inflammatory Bowel Disease Questionnaire (SIBDQ)
Time frame: Baseline and at every 6 months (up to 7 years)
The Short IBD Questionnaire is an instrument used to assess quality of life and is a disease-specific health-related quality of life questionnaire, that consists of 10 questions, each question is scored on a scale from 1 (poor quality of life) to 7 (good quality of life). The scores are summed up and divided by 10 for a mean score ranging from 1 (poor quality of life) to 7 (good quality of life). A higher score indicates a better health-related quality of life.
-
Participant Reported Quality of Life Assessment Using 12-Item Short Form Health Survey (SF-12)
Time frame: Baseline and at every 6 months (up to 7 years)
The SF-12 health questionnaire is a 12 question assessment of functional health and well-being. The survey asks about various health aspects, including physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health (psychological distress and psychological well-being). Two summary measures are derived: the Physical and the Mental Health Component Summary. For each component summary, survey items were weighted and summed to create a summary score between 0 and 100 with higher score indicating better quality of life.
-
Time to Treatment Discontinuation
Time frame: Baseline and at every 6 months (up to 7 years)
Time to discontinuation for Entyvio and the other biologic agents will be measured.
-
Reasons for Treatment Discontinuation
Time frame: Baseline and at every 6 months (up to 7 years)
Reasons for discontinuations for Entyvio and the other biologic agents will be measured.
Sponsors and collaborators
Lead sponsor
Takeda
Industry
Registry information
Official study title
Entyvio (Vedolizumab) Long-term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis or Crohn's Disease
Acronym: Entyvio PASS
Important dates
- Study start
- 2015
- Primary completion
- 2021
- Study completion
- 2021
- First posted
- Feb 4, 2016
- Registry last updated
- Oct 31, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Study of the Role of Pomegranate Juice Ellagitannins in the Modulation of Inflammation in Inflammatory Bowel Disease
NCT03000101
Colitis, Colitis, Ulcerative
Bologna, Italy
View Trial DetailsAssessing Interventions of Diet in IBD
NCT06773182
Behavior, Colitis
Hamilton, Ontario, Canada
View Trial DetailsNarrow Band Imaging Versus Artificial Intelligence for Colonic Surveillance in Inflammatory Bowel Disease
NCT07694362
Artificial Intelligence (AI), Chromoendoscopy
Barcelona, Catalonia, Spain
View Trial DetailsIBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms
NCT06094608
Colitis, Colitis, Ulcerative
Ann Arbor, Michigan, United States
View Trial Details